Decision Resources expects robust growth thru 2015, based on STI approvals.
Also, I didn't realize it, but NVS' Gleevec successor is now dubbed "Tasigna." I wonder why they didn't build off the Gleevec recognition? (Gleesigna?)
Clinical data for Tasigna looks great, per the press releases.
Separately, NVS has announced an intent to file for Tasigna approval before the end of the year.
Monday, November 27, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment